Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Issue 1 (January 2014)

• Record Type: Journal Article
• Authors: Berahovich, Robert D.; Zabel, Brian A.; Lewén, Susanna; Walters, Matthew J.; Ebsworth, Karen; Wang, Yu; Jaen, Juan C.; Schall, Thomas J.
• Is Part Of: Immunology. Volume 141:Issue 1(2014:Jan.)
• Page Start: 111
• Page End: 122
• Publication Date: 2014-01
• Subjects: Immunology -- Periodicals
• DOI: 10.1111/imm.12176
• Languages: English
• ISSNs: 0019-2805

Abstract

<abstract abstract-type="main" id="imm12176-abs-0001"> <title>Summary</title> <p>The concentration of CXCL12/SDF‐1 in the bloodstream is tightly regulated, given its central role in leucocyte and stem/progenitor cell egress from bone marrow and recruitment to sites of inflammation or injury. The mechanism responsible for this regulation is unknown. Here we show that both genetic deletion and pharmacological inhibition of CXCR7, a high‐affinity CXCL12 receptor, caused pronounced increases in plasma CXCL12 levels. The rise in plasma CXCL12 levels was associated with an impairment in the ability of leucocytes to migrate to a local source of CXCL12. Using a set of complementary and highly sensitive techniques, we found that CXCR7 protein is expressed at low levels in multiple organs in both humans and mice. In humans, CXCR7 was detected primarily on venule endothelium and arteriole smooth muscle cells. CXCR7 expression on venule endothelium was also documented in immunodeficient mice and CXCR7^+/lacZ mice. The vascular expression of CXCR7 therefore gives it immediate access to circulating CXCL12. These studies suggest that endothelial CXCR7 regulates circulating CXCL12 levels and that CXCR7 inhibitors might be used to block CXCL12‐mediated cell migration for therapeutic purposes.</p> </abstract>